Navigation Links
Ranbaxy Announces Improved Business Standards and Quality Assurance Initiatives
Date:5/22/2013

TOKYO, May 22, 2013 /PRNewswire/ -- Ranbaxy Laboratories Limited (hereafter, Ranbaxy), a subsidiary of Daiichi Sankyo Co., Ltd. (hereafter, Daiichi Sankyo), announced on May 22 the actions that Ranbaxy has taken in recent years to address past conduct under prior management

(http://www.daiichisankyo.com/media_investors/media_relations/press_releases/index.html).

Daiichi Sankyo continues to support Ranbaxy in its efforts to address and correct the conduct of the past which led to the investigations by the U.S. Department of Justice ("DOJ") and the U.S. Food and Drug Administration ("USFDA"). These efforts include significant changes to Ranbaxy's management, culture, operations and compliance.

Daiichi Sankyo believes that certain former shareholders of Ranbaxy concealed and misrepresented critical information concerning the U.S. DOJ and FDA investigations. Daiichi Sankyo is currently pursuing its available legal remedies and cannot comment further on the subject at this time.

About Daiichi Sankyo Co., Ltd.
Listed: Code No.: 4568, First Section of Tokyo, Osaka and Nagoya Stock Exchanges
President and CEO: Joji Nakayama

Contact:
Noriaki Ishida
Corporate Officer & Vice President
Corporate Communications Department
Daiichi Sankyo Co., Ltd.
Tel: +81-3-6225-1126
e-mail: kondo.toshiya.cj@daiichisankyo.co.jp

http://www.daiichisankyo.com/


'/>"/>
SOURCE Daiichi Sankyo Co., Ltd.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Statement By Dinesh Thakur Regarding US Governments Case Against Ranbaxy
2. Indias Largest Generic Drugmaker Ranbaxy Pays $500 Million to Settle Systemic Generic Drug Manufacturing Fraud
3. Ranbaxy to Market Desvenlafaxine Base Extended Release Tablets in the U.S.
4. Ranbaxy Issues Voluntary Nationwide Recall of 41 lots of Atorvastatin Calcium Tablets 10 mg, 20 mg and 40 mg Due to Potential Presence of Foreign Substance
5. Ranbaxy Launches Authorized Generic Of Pioglitazone In The U.S.
6. Ranbaxy Commends New IMS Study Which Credits Generic Prescription Drugs With $1 Trillion Savings In U.S. Health Care Costs Over Past 10 Years
7. Ranbaxy Announces U.S. FDA Approval of CIP-Isotretinoin NDA
8. Ambit Biosciences Announces Presentations of Data from Clinical Investigations of Quizartinib at the Annual Meeting of the American Society of Clinical Oncology
9. Cellular Biomedicine Group Announces Enrollment Milestone for Phase I Clinical Trial for Liver Cancer
10. OncoGenex Announces Multiple Trials in Progress Presentations at the 2013 ASCO Annual Meeting
11. Elbit Imaging Announces the Court Decision with Respect to Filing of Plan of Arrangement with the Israeli Court
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... April 20, 2017  Cogentix Medical, Inc. (NASDAQ: ... providing the Urology, Uro/Gyn and Gynecology markets with ... Keswani has joined the Company as Senior Vice ... created position, Mr. Keswani will report directly to ... "Our organization is delighted that Ash has ...
(Date:4/20/2017)... Mass. , April 20, 2017  RXi ... developing innovative therapeutics that address significant unmet medical ... data from the Company,s consumer product development program, ... at the Society for Investigative Dermatology (SID) 76 ... to advance and promote the sciences relevant to ...
(Date:4/20/2017)... April 20, 2017  AbbVie (NYSE: ABBV), a ... (n=145/146) of chronic hepatitis C virus (HCV) infected ... 6 and compensated cirrhosis (Child-Pugh A) achieved sustained ... ) with its investigational, pan-genotypic regimen of glecaprevir/pibrentasvir ... seen following 12 weeks of G/P treatment without ...
Breaking Medicine Technology:
(Date:4/25/2017)... ... April 25, 2017 , ... ... committed to raising awareness for Duchenne muscular dystrophy, and funding for Duchenne ... (cardiosphere-derived cells) Phase I/II HOPE clinical trial in Duchenne announced today. , ...
(Date:4/25/2017)... ... April 25, 2017 , ... Lake Park Dental is now accepting ... Invisalign® in Lutz, FL. With the help of this highly-effective, yet convenient system, ... potential complications, more discretion and less pain. , Drs. Sarah Jockin, Nicole Morganti, ...
(Date:4/25/2017)... ... April 25, 2017 , ... Buyers and sellers in the thriving ... and head shops –can’t help but be heartened by the industry’s current surge. But ... aptly described as “skunk smell.” At last they can simply, safely and effectively ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... healthcare products, is introducing Flexadin UCII, part of the EQUISTRO line, at this ... joint health in horses at the immunologic level. , The scientifically-developed Flexadin UCII ...
(Date:4/24/2017)... ... 24, 2017 , ... The Santana Telehealth Project was honored with the 2017 ... American Telemedicine Association’s annual conference, on April 23 in Orlando, FL. , “I am ... the lives of the poor and underserved in other parts of the world,” said ...
Breaking Medicine News(10 mins):